· Significantly higher sales of Synagis following increased demand as a result of improved commercial effectiveness and wholesaler stocking. In addition, sales increased due to a positive Gross-to-Net impact and a more severe RSV season than normal
· Higher Gamifant sales reflecting higher average patient weight and longer treatment periods
· Better performance of Orfadin and other Specialty Care products mainly due to phasing of large orders.
The main period of the RSV season spans from the fourth quarter to the first quarter why sales of Synagis shall be evaluated over a full period (Q4-Q1). Gamifant is still in launch phase and continued volatility is expected going forward due to the ultra-rare nature of the disease and the limited patient population.
At the publication of the Q3 2019 report on 31 October Sobi reiterated the outlook for the FY year 2019 published on
Sobi will announce its fourth quarter and full year 2019 report on Thursday
About Sobi
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,300 people across
This information is information that
For more information please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 708 734 095
linda.holmstrom@sobi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-s-full-year-2019-revenue-and-ebita-higher-than-previous-estimates,c3010175
https://mb.cision.com/Main/14266/3010175/1175348.pdf
(c) 2020 Cision. All rights reserved., source